Pulmonx has developed the Zephyr Endobronchial Valve, a minimally invasive treatment for COPD/emphysema. The one-time procedure is done by bronchoscopy and requires no cutting or incisions. During the procedure, on average 4 tiny valves are placed in the airways to block off the diseased parts of the lung which allows trapped air to escape until the lobe is reduced. Reducing hyperinflation allows the healthier parts of the lungs to expand and take in more air. This results in patients being able to breathe easier and have less shortness of breath.1


Medical Devices

Pulmonx

Glendon E. French

Manu Joshi

Nick Pizzuti

Jon Biggs

Laure F.

Narinder Singh Shargill

Martin Schneider

Young Lee

Todd Galski

Tanner Johnson

Steve Wallace P.e.

Jim Outlaw

Jim Bobbitt

Conor McGuire

William Long

Marcee Maroney

Lisa Paul

Anna Gawlicka

David Lehman

Narinder S. Shargill

Mahtab Fatemi

Jérôme Erath

Sarah Huber

Kelly M. Shriner

Beran Rose

Sri Radhakrishnan

The Research and Development team at Pulmonx focuses on innovating and enhancing the Zephyr Endobronchial Valve technology. Their work involves designing, developing, and testing new product features and functionalities to improve treatment outcomes for COPD/emphysema patients. They collaborate closely to ensure the efficacy and safety of the valves through rigorous engineering and software development processes.

Research and Development

Sales Team

Leadership Team

Marketing

Research and Development

About

Team members

Other teams at Pulmonx

Sales Team

Leadership Team

Marketing